In the ongoing reshaping of global healthcare, Apollo Global Management has emerged as a prospective buyer of Johnson & Johnson's orthopedics division — a business valued at roughly $20 billion that spans joint replacements, trauma devices, and surgical solutions. The reported interest reflects a broader pattern in which private equity firms, flush with uninvested capital, are drawn to the demographic certainty of aging populations and the relative resilience of medical device revenue. For J&J, long engaged in portfolio refinement since spinning off its consumer health arm, a divestiture of th